Patent · US Active

Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

US12054497B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

Inventors

Fusheng ZHOU · Shanghai, CN
Tao Jiang · San Diego, US
Chonglan LIN · Shanghai, CN
Lijian CAI · Shanghai, CN
Wan HE · Shanghai, CN
Jiong Lan · Moraga, US

Key dates

Filing date	Oct 28, 2020
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Oct 28, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/22
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.